Advanced search
1 file | 4.27 MB Add to list

Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)
(2020) NPJ VACCINES. 5(1).
Author
Organization
Abstract
Annual administration and reformulation of influenza vaccines is required for protection against seasonal infections. However, the induction of strong and long-lasting T cells is critical to reach broad and potentially lifelong antiviral immunity. The NLRP3 inflammasome and its product interleukin-1 beta (IL-1 beta) are pivotal mediators of cellular immune responses to influenza, yet, overactivation of these systems leads to side effects, which hamper clinical applications. Here, we present a bypass around these toxicities by targeting the activity of IL-1 beta to CD8(+)T cells. Using this approach, we demonstrate safe inclusion of IL-1 beta as an adjuvant in vaccination strategies, leading to full protection of mice against a high influenza virus challenge dose by raising potent T cell responses. In conclusion, this paper proposes a class of IL-1 beta-based vaccine adjuvants and also provides further insight in the mechanics of cellular immune responses driven by IL-1 beta.
Keywords
MEMORY T-CELLS, DENDRITIC CELLS, INFLUENZA-VIRUS, EXPRESSION, EFFECTOR, SURVIVAL, CD8, INTERLEUKIN-1, RECOGNITION, RESPONSES

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 4.27 MB

Citation

Please use this url to cite or link to this publication:

MLA
Van Den Eeckhout, Bram, et al. “Specific Targeting of IL-1β Activity to CD8+ T Cells Allows for Safe Use as a Vaccine Adjuvant.” NPJ VACCINES, vol. 5, no. 1, 2020, doi:10.1038/s41541-020-00211-5.
APA
Van Den Eeckhout, B., Van Hoecke, L., Burg, E., Van Lint, S., Peelman, F., Kley, N., … Gerlo, S. (2020). Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant. NPJ VACCINES, 5(1). https://doi.org/10.1038/s41541-020-00211-5
Chicago author-date
Van Den Eeckhout, Bram, Lien Van Hoecke, Elianne Burg, Sandra Van Lint, Frank Peelman, Niko Kley, Gilles Uzé, Xavier Saelens, Jan Tavernier, and Sarah Gerlo. 2020. “Specific Targeting of IL-1β Activity to CD8+ T Cells Allows for Safe Use as a Vaccine Adjuvant.” NPJ VACCINES 5 (1). https://doi.org/10.1038/s41541-020-00211-5.
Chicago author-date (all authors)
Van Den Eeckhout, Bram, Lien Van Hoecke, Elianne Burg, Sandra Van Lint, Frank Peelman, Niko Kley, Gilles Uzé, Xavier Saelens, Jan Tavernier, and Sarah Gerlo. 2020. “Specific Targeting of IL-1β Activity to CD8+ T Cells Allows for Safe Use as a Vaccine Adjuvant.” NPJ VACCINES 5 (1). doi:10.1038/s41541-020-00211-5.
Vancouver
1.
Van Den Eeckhout B, Van Hoecke L, Burg E, Van Lint S, Peelman F, Kley N, et al. Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant. NPJ VACCINES. 2020;5(1).
IEEE
[1]
B. Van Den Eeckhout et al., “Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant,” NPJ VACCINES, vol. 5, no. 1, 2020.
@article{8671043,
  abstract     = {{Annual administration and reformulation of influenza vaccines is required for protection against seasonal infections. However, the induction of strong and long-lasting T cells is critical to reach broad and potentially lifelong antiviral immunity. The NLRP3 inflammasome and its product interleukin-1 beta (IL-1 beta) are pivotal mediators of cellular immune responses to influenza, yet, overactivation of these systems leads to side effects, which hamper clinical applications. Here, we present a bypass around these toxicities by targeting the activity of IL-1 beta to CD8(+)T cells. Using this approach, we demonstrate safe inclusion of IL-1 beta as an adjuvant in vaccination strategies, leading to full protection of mice against a high influenza virus challenge dose by raising potent T cell responses. In conclusion, this paper proposes a class of IL-1 beta-based vaccine adjuvants and also provides further insight in the mechanics of cellular immune responses driven by IL-1 beta.}},
  articleno    = {{64}},
  author       = {{Van Den Eeckhout, Bram and Van Hoecke, Lien and Burg, Elianne and Van Lint, Sandra and Peelman, Frank and Kley, Niko and Uzé, Gilles and Saelens, Xavier and Tavernier, Jan and Gerlo, Sarah}},
  issn         = {{2059-0105}},
  journal      = {{NPJ VACCINES}},
  keywords     = {{MEMORY T-CELLS,DENDRITIC CELLS,INFLUENZA-VIRUS,EXPRESSION,EFFECTOR,SURVIVAL,CD8,INTERLEUKIN-1,RECOGNITION,RESPONSES}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{17}},
  title        = {{Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant}},
  url          = {{http://dx.doi.org/10.1038/s41541-020-00211-5}},
  volume       = {{5}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: